Acelrx Pharmaceuticals Inc FCF yield
What is the FCF yield of Acelrx Pharmaceuticals Inc?
The FCF yield of Acelrx Pharmaceuticals Inc is -6.64%
What is the definition of FCF yield?
Free cash flow yield (FCF yield) is a financial ratio that compares the free cash flow per share to the market value per share. The ratio is calculated by dividing free cash flow per share by the current share price.
ttm (trailing twelve months)
Free cash flow yield is a good measure of the company’s cash flow in respect to the company’s size. Larger companies tend to have a higher cash flow yield, but it’s not always the case. The higher the free cash flow yield, the more cash the company is generating that can be quickly accessed to satisfy its obligations. The lower the free cash flow yield, the more money investors are putting into the company with little result. The higher the ratio, the more attractive the investment is as it suggests that investors are paying less for each unit of free cash flow.
Free cash flow acts as an indicator of how capable a company is of repaying all of its obligations. It is a solid indicator of how financially stable a company is. It is calculated as:
Free cash flow yield = Free cash flow per share / market price per share
FCF yield of companies in the Health Care sector on NASDAQ compared to Acelrx Pharmaceuticals Inc
What does Acelrx Pharmaceuticals Inc do?
acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v
Companies with fcf yield similar to Acelrx Pharmaceuticals Inc
- Gold Reserve has FCF yield of -6.67%
- Western Magnesium has FCF yield of -6.66%
- Myriad Genetics has FCF yield of -6.66%
- Hylands International has FCF yield of -6.65%
- Cassiar Gold Corp has FCF yield of -6.65%
- Freeman Gold has FCF yield of -6.65%
- Acelrx Pharmaceuticals Inc has FCF yield of -6.64%
- Peninsula has FCF yield of -6.63%
- Maiden Ltd has FCF yield of -6.62%
- Galantas Gold has FCF yield of -6.62%
- Centerpoint has FCF yield of -6.62%
- Maple Gold Mines has FCF yield of -6.62%
- Candente Copper has FCF yield of -6.62%